Michael Offin - Concepedia

Author

Michael Offin

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

M. Offin, M.D. Offin, Michael D Offin, Michael D. Offin, Michael David Offin, Michael Offin, Offin, Michael, Offin,Michael

426

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Dana-Farber Cancer Institute Molecular Oncology (United States)Massachusetts General Hospital

About

Michael Offin is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	33	2.5K
2	Health Sciences	6	6	326
3	Cell Biology	6	6	654
4	Engineering	1	1	30
5	Natural Sciences	1	1	15

Michael Offin

Publications

Citations

H-Index

Page 1

	Year	Citations
Ado-Trastuzumab Emtansine for Patients With <i>HER2</i>-Mutant Lung Cancers: Results From a Phase II Basket Trial Bob T. Li, Ronglai Shen, Darren J. Buonocore, Journal of Clinical Oncology Tumor BiologyPartial Response RateMedicineImmunologyMass Spectrometry	2018	541
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden Ryma Benayed, Michael Offin, Kerry Mullaney, Clinical Cancer Research	2019	466
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes Michael Offin, Joseph M. Chan, Megan Tenet, Journal of Thoracic Oncology Tumor BiologyMedicinePathologyTp53 Alterations DefineBronchial Neoplasm	2019	428
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer Joseph M. Chan, Àlvaro Quintanal-Villalonga, Vianne R. Gao, Cancer Cell	2021	396
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i> -Mutant Lung Cancers Michael Offin, Hira Rizvi, Megan Tenet, Clinical Cancer Research	2018	323
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers Joshua K. Sabari, Giulia C. Leonardi, Catherine A. Shu, Annals of Oncology	2018	315
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers Bob T. Li, Flavia Michelini, Sandra Misale, Cancer Discovery	2020	274
COVID-19 in patients with lung cancer Jie Luo, Hira Rizvi, Isabel R. Preeshagul, Annals of Oncology MedicineCovid-19 PandemicCovid-19 EpidemiologyOncologyLung Cancer	2020	267
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers Alexander Drilon, Thomas Filleron, Ai Ni, Journal of Thoracic Oncology	2018	226
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer Justin Jee, Emily S. Lebow, Randy Yeh, Nature Medicine Tumor Dna-guided TherapyOverall SurvivalMedicineBronchial NeoplasmCancer Treatment	2022	170

Page 1